Clinical trial
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus
NCT07684144 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 29, 2026
- Completion date
- March 19, 2028
- Enrollment
- 950 (estimated)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.